Effectiveness of Vitamin B1-6-12 Supplementation Compared With Vitamin B12 and Gabapentin in Patients With Diabetic Peripheral Neuropathy

The use of gabapentin, a first-line drug for diabetic peripheral neuropathy (DPN), is limited by its side effects, leading to more frequent use of vitamin B as an alternative. This randomized controlled trial of 237 patients with diabetes and at least probable DPN assessed pain outcomes using the Revised Thai Short-Form McGill Pain Questionnaire, Visual Analog Scale, Present Pain Intensity, and monofilament risk score at baseline and 4 and 12 weeks. Gabapentin showed superior improvement across all measures compared with vitamin B1-6-12 and B12, supporting its role as first-line therapy. However, vitamin B1-6-12 remains a cost-effective alternative with lower side effect, warranting further economic evaluation.